This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Focal therapy using high intensity focussed ultrasound (HIFU) for localised prostate cancer

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Focal therapy using high intensity focussed ultrasound (HIFU) is intended to be used in patients with localised prostate cancer - specifically patients with tumours that are confined to 1 prostatic lobe

  • imaging and biopsy mapping studies are used to confirm that the tumour is suitable for focal therapy and to show its precise location
    • with the patient under local or general anaesthesia, the bladder is catheterised and the HIFU probe is inserted transrectally
      • real-time ultrasound imaging guidance and/or magnetic resonance guidance is used to position the probe and to monitor the procedure
      • pulses of HIFU are directed at the targeted part of the prostate, inducing tumour necrosis by a thermal effect and causing cavitation (which can be visualised by ultrasound to assess the adequacy of treatment) until satisfactory ablation of the target area is judged to have occurred

  • after treatment patients are usually followed up regularly with prostate-specific antigen (PSA) measurements, imaging, and repeated biopsies to detect recurrence
  • NICE have suggested HIFU as a management option for localised prostate cancer (1)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.